Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03734692 · ClinicalTrials.gov registry record · Phase 1

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

A Phase 1 study of Ovarian Cancer Recurrent, sponsored by Robert Edwards.

Active
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT03734692 is a Phase 1 study of Ovarian Cancer Recurrent that is active but no longer recruiting, run by Robert Edwards. The registered enrollment target is 24 participants, below the 131-participant average among 4 other Ovarian Cancer Recurrent trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03734692, a Phase 1 study of Ovarian Cancer Recurrent, is active but no longer recruiting, sponsored by Robert Edwards.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This is a phase II single arm efficacy/safety trial that will evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP rintatolimod (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (IVP) for patients with recurrent platinum-sensitive ovarian cancer (OC).

Conditions Studied

Ovarian Cancer Recurrent

Interventions

  • DRUG Pembrolizumab
  • DRUG Cisplatin
  • DRUG Rintatolimod

Study Locations (1)

Pennsylvania

  • Magee-Womens Hospital of UPMC - Pittsburgh

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2019-01-28
Est. Completion 2027-01-10
Phase Phase 1

Sponsor

Robert Edwards

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03734692

The ClinicalTrials.gov registry entry for NCT03734692 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 4 other Ovarian Cancer Recurrent trials with a reported enrollment target (82% lower). The listed sponsor is Robert Edwards, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ovarian Cancer Recurrent appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.

NCT03734692 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03734692 about?

NCT03734692 is a clinical study titled "Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer". This is a phase II single arm efficacy/safety trial that will evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with IP rintatolimod (TLR-3 agonist) and IV infusion of the checkpoint inhibitor pembrolizumab (IVP) for patients with rec...

What is the current status of trial NCT03734692?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2019-01-28. Estimated completion is 2027-01-10.

What conditions does trial NCT03734692 study?

This clinical trial studies the following conditions: Ovarian Cancer Recurrent.

What interventions are being tested in trial NCT03734692?

The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Rintatolimod (DRUG).

Who is sponsoring clinical trial NCT03734692?

This trial is sponsored by Robert Edwards, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03734692 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer Recurrent

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer Recurrent

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.